Skip to main content

Talk Bio

Search This Blog

Karoo Health Raises $16.2 Million to Expand AI‑Driven Cardiovascular Care Platform

on July 24, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

Karoo Health, an Albuquerque-based cardiovascular technology startup, has raised $16.2 million in an oversubscribed Series A funding round to expand its AI-native platform for detecting and managing cardiovascular conditions.

The round was co-led by healthcare investors 7wire Ventures and Allumia Ventures, with participation from First Trust Capital Partners, SpringRock Ventures, Hyde Park Angels, and other investors.

Karoo Health plans to use the funds to advance its AI-driven predictive models and clinical signal-detection capabilities, scale its care coordination infrastructure, and expand engineering and clinical teams working with health plans and cardiology practices.

Sources:

Karoo Health Raises $16.2 Million Series A To Expand ...

Ian Koons' Post

Exclusive: Karoo Health raises $16.2 M Series A

Karoo Health Announces Oversubscribed $16.2 Million ...

Karoo Health Raises $16.2M in Series A Funding

Karoo Health has closed an oversubscribed $16.2 million Series A round co-led by 7wire Ventures and Allumia Ventures to advance its AI-native cardiovascular platform.

Exclusive: Karoo Health raises $16.2M Series A

Karoo Health Secures $16

Karoo Health — $16M Raised | 1 Round | AI Funding

Karoo Health Seeds $3M for Value-Based Heart Care | DealFlow's ...

Health tech startup raises $16M >> See the full article ...

Karoo Health raises $3M seed for value-based heart care

Matt S. on LinkedIn: Karoo Health Raises $3.4 Million in Oversubscribed Seed Round

Karoo Health Raises $3.4 Million in Oversubscribed Seed ...

Karoo Health Raises $3.4 Million in Oversubscribed Seed ...

AI-native platform Allumia Ventures cardiovascular conditions care coordination Funding Karoo Health predictive models Series A Ventures

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer

Rivus Pharmaceuticals announced on February 25, 2026, the appointment of Jorge Bartolome as Chief Executive Officer and Board member, succeeding co-founder Allen Cunningham who transitions to Chief Operating Officer. 1 2 Jorge Bartolome brings over 25 years of experience, including CEO of AreteiaTx, President of Janssen Canada, and senior roles at GSK generating $8 billion in sales. 1 2 Rivus focuses on oral therapies for MASH, obesity, and cardiometabolic diseases, with lead candidate HU6 (oral mitochondrial uncoupler) succeeding in three Phase 2 trials. 1 2 2026 plans include advancing HU6 in the AMPLIFY Phase 2 trial for MASH and initiating first clinical trial for RV-8451, an oral muscle-preserving GLP-1 for obesity. 1 2 Ian F. Smith, Co-Chair of the Board, highlighted Bartolome's expertise in late-stage development and commercialization as ideal for Rivus' growth. 1 2 Sources: 1. https://www.globenewswire.com/news-release/2026/02/25/3244576/0/en/Rivus-Pharmaceu...

OKYO Pharma Appoints Flavio Mantelli, MD, PhD as Chief Medical Officer

OKYO Pharma announced on February 10, 2026, the appointment of Flavio Mantelli, MD, PhD, as Chief Medical Officer to lead clinical and regulatory strategy for urcosimod in neuropathic corneal pain (NCP). Dr. Mantelli previously served as CMO at Dompé, where he led the clinical development, FDA approval, and global strategy for Oxervate®, a blockbuster orphan drug with over $1 billion in sales in 2024. Urcosimod has FDA Fast Track designation for NCP, with a planned ~150-subject Phase 2b/3 multiple-dose study expected to start in H1 2026. This appointment follows the recent hiring of CEO Robert Dempsey and strengthens OKYO's ophthalmology leadership team. OKYO Pharma shares rose 10.80% intraday following the announcement. Sources:

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Powered by Blogger

X-Data LLC